Raffles Medical (RM) just announced its Q2 2017 results.
 
Results Overview
At first glance, RM’s Revenue, Ops Income and Net Income for Q2 remained constant or showed marginal fall over Q1 respectively: 1%, -1.9%, -2.3%.
 
Its Net Cashflow from Ops of $23.6m is similar to the $23.8m in Q1.
 
Balance sheet remains strong, with $112m cash and only $53m loans and borrowings.
 
All in all, results seem fine.
 
But its share price is a different story. It dropped about 5% to $1.21 on 1 Aug, one day after its result release, and fell further to $1.185 on 2 Aug afternoon. That is about an 8% drop since result announcement.   
 
This piqued my interest. RM has been on my watch list for long and I am interested to know if this is a good chance to start accumulating the shares.
 
RM Traded at …